Skip to main content

Josh Schafer

Analyst

Equibles does not estimate personal net worth.

About Josh Schafer

Josh Schafer has spoken on 3 earnings calls across 1 company, most recently for Zevra Therapeutics, Inc. on August 5, 2026. The companies whose calls Josh Schafer spoke on are classified in the Healthcare sector.

Josh Schafer on recent calls

“NPC is an ultra-rare genetic disease that causes significant neurological impairment and places a substantial burden on patients and families. Clinical manifestations can include dysfunction of ambulation, fine motor skills, swallowing, and speech.”
Zevra Therapeutics, Inc. Q2 FY2026 Earnings Call ·
“We're seeing initially you know as we expected that the early patients were coming from those clinicians who were part of our EAP and those are largely neurologists and pediatricians now keep in mind that while many of these clinicians might have a have done training as a pediatrician they are seeing both both…”
Zevra Therapeutics, Inc. Q2 FY2025 Earnings Call ·
“2024 was a year of significant milestones for Zebra and the rare disease community. In particular, The FDA's approval of MyPlypha marked the first product in the U.S. for the treatment of NPC.”
Zevra Therapeutics, Inc. Q4 FY2024 Earnings Call ·

Company network

Recent activity